Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basic treatment considerations: chemotherapy.

Sakkaraiappan Ramalingam1, Chandra P Belani

  • 1Division of Hematology-Oncology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, 5150 Center Avenue, UPMC Cancer Pavilion, Pittsburgh, PA 15232, USA.

Hematology/Oncology Clinics of North America
|March 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data.

JTO clinical and research reports·2026
Same author

Machine learning integrated extracellular vesicle proteome analysis for early markers of bronchopulmonary dysplasia.

Function (Oxford, England)·2026
Same author

Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having <i>EGFR</i> Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer-American Society of Clinical Oncology CancerLinQ Study.

JTO clinical and research reports·2024
Same author

Characterization of effective, simple, and low-cost precipitation methods for depleting abundant plasma proteins to enhance the depth and breadth of plasma proteomics.

Proteomics·2024
Same author

International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2023
Same author

Design of experiments approach for systematic optimization of a single-shot diaPASEF plasma proteomics workflow applicable for high-throughput.

Proteomics. Clinical applications·2023

Lung cancer remains a significant global health issue. Recent advancements in chemotherapy and combined modality treatments offer improved outcomes for advanced and locally advanced non-small cell lung cancer (NSCLC), with targeted therapies under investigation.

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Background:

  • Lung cancer is a leading cause of global mortality, often diagnosed at advanced stages due to a lack of effective screening.
  • Significant progress has been made in treating advanced non-small cell lung cancer (NSCLC) over the last two decades.

Purpose of the Study:

  • To review recent advancements in lung cancer treatment, focusing on chemotherapy, combined modality therapy, and targeted therapies.
  • To highlight the current challenges and future directions in improving patient outcomes for lung cancer.

Main Methods:

  • Review of recent clinical trials and therapeutic developments in lung cancer treatment.
  • Analysis of chemotherapy agents, combination therapies, and molecularly targeted approaches.

Related Experiment Videos

Main Results:

  • Novel chemotherapy agents show efficacy with favorable toxicity profiles.
  • Combined modality therapy (radiation and chemotherapy) improves outcomes for locally advanced NSCLC, offering curative potential.
  • Initial results of molecularly targeted therapies have been disappointing, but further research is ongoing.

Conclusions:

  • Chemotherapy improves survival and quality of life for patients with stage IIIB/IV NSCLC.
  • Integrated treatment strategies are crucial for improving lung cancer patient outcomes.
  • Effective incorporation of molecularly targeted therapies into existing treatment paradigms is a key future goal.